Q-omics provides the consensus-scored KCTD5 profile across patient tissues and cancer cell-line models. KCTD5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KCTD5 is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, KCTD5 RNA expression shows 19,203 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, and ACC as cancer lineages where KCTD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCTD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCTD5 survival associations across molecular data types. KCTD5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCTD5 RNA expression–survival associations across cancer types. High KCTD5 expression shows unfavorable associations in KIRP, MESO, ACC, LIHC and BRCA, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for KCTD5 RNA expression.
This table summarizes KCTD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KCTD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCTD5 shows higher tumor expression in KIRP, HNSC, KIRC, LUAD, LIHC and STAD. The KIRP box plot shows higher KCTD5 RNA expression in tumor versus normal tissue (log2 FC = +1.078, t-test p < 0.001).
This table shows molecular features associated with KCTD5 in patient tissues and cancer cell lines. In patient samples, KCTD5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCTD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
